F tier · safety concern
PubMed returns no records at all for ‘vesilute’ — the engine reports the term retrieved no results and silently substitutes an unrelated word — and ClinicalTrials.gov has no registered study. Its identity is also unsettled: the originator's own product declares only a peptide complex of aspartic and glutamic acid, while Western vendors variously sell it as Glu-Asp or as Lys-Glu-Asp with a CAS number that does not match the Lys-Glu-Asp record in PubChem.
vesilute
Vesilute, sold in Russia as Vesilut, is a bladder-directed product in the Cytogens consumer range associated with Khavinson's St Petersburg institute. Unlike the defined bioregulator peptides it has no established sequence: the originator's listing declares an active called ‘peptide AKS-M (L-aspartic acid; L-glutamic acid)’ in an oral capsule with cellulose, lactose and starch, while Western research-reagent vendors describe it inconsistently as the dipeptide Glu-Asp, as the tripeptide Lys-Glu-Asp, and in at least one case as a vascular rather than urinary bioregulator. There is no indexed scientific literature on it and no registered trial.
the explanation
Vesilute is sold as a peptide for the bladder, but nobody can agree what it actually is — the Russian original is a capsule listing only aspartic and glutamic acid, while Western sellers describe two or three different amino acid sequences and one even calls it a blood-vessel peptide. There is not a single scientific paper about it in the medical literature database, and no clinical trial has ever been registered. Everything claimed for it is borrowed from other products.
regulatory status
No medicinal approval anywhere; supplement-category product in Russia, research reagent in the UK
Vesilut holds no marketing authorisation as a medicine in the UK, EU, US or Russia. In Russia it reaches consumers as an oral capsule in the Cytogens range, produced by TD Peptid Bio in association with the St Petersburg Institute of Bioregulation and Gerontology, that is, as a supplement-category product rather than a registered pharmaceutical, and its listing makes therapeutic-sounding claims about cystitis, prostatitis, incontinence and benign prostatic hyperplasia that no regulator has assessed. A ClinicalTrials.gov search returns no registered study. In Great Britain it has no authorisation, is not a controlled drug, and is not an approved novel-food or food-supplement ingredient; because its composition is not established, it could not be assessed as either a medicine or a food ingredient here even in principle, and it is lawfully supplied only as a laboratory research reagent. It is not named on the WADA Prohibited List, but an unidentifiable preparation would fall under the S0 unapproved-substances class.
how it works · proposed mechanism
No compound-specific mechanism has been published for Vesilute, because no study of Vesilute has been published. What is offered instead is the family-level hypothesis, applied by analogy to a molecule whose identity is not fixed.
Family hypothesis applied by analogy
The Khavinson model holds that ultrashort peptides enter cell nuclei and bind promoter regions, with the amino-acid composition determining which organ is affected. Vesilute is assigned bladder specificity on that logic alone; no docking study, gene-expression experiment or tissue study naming Vesilute was located in any database.
An unresolved active substance
The originator's listing names ‘peptide AKS-M (L-aspartic acid; L-glutamic acid)’, implying a Glu-Asp-based material, while a research-reagent vendor sells it as H-Lys-Glu-Asp-OH with the molecular formula and mass of Vesugen but a CAS number that does not match PubChem's Lys-Glu-Asp record. A mechanism cannot be attributed to a molecule that has not been identified.
Borrowed clinical narrative
Clinical-sounding bladder claims in this space largely trace to Vesusten, a different preparation — a complex of regulatory peptides extracted from bovine bladder tissue — for which a Russian urology review describes phase I in 32 volunteers and randomised placebo-controlled phase II and phase III studies in 108 and 150 patients with overactive bladder. Those data belong to Vesusten, not to Vesilute, and are also not registered on ClinicalTrials.gov.
Cross-contaminated marketing
At least one Western vendor lists Vesilute as a ‘vascular bioregulator’, which is Vesugen's claimed indication, while others give bladder-specific outcome anecdotes with no citation. The inconsistency is itself diagnostic: the marketing is assembled from neighbouring products rather than from any evidence about this one.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Vesilute is the weakest entry in this family because there is nothing to assess: PubMed retrieves no records for the name, ClinicalTrials.gov has no registered study, and the compound's own identity is contested. The originator's product declares only ‘peptide AKS-M (L-aspartic acid; L-glutamic acid)’ in a capsule of cellulose, lactose and starch; one research-reagent vendor sells it as H-Lys-Glu-Asp-OH — which is Vesugen — with CAS 76101-86-5, a number that does not match PubChem's Lys-Glu-Asp record of 204271-66-9; another describes it as Glu-Asp; another labels it a vascular bioregulator, which is Vesugen's claim again. Meanwhile the bladder-peptide clinical data that circulates in marketing copy appears to belong to Vesusten, a bovine bladder peptide complex whose Russian phase II and III studies in 108 and 150 overactive-bladder patients are a different preparation entirely, and are themselves unregistered. Every chemistry field for Vesilute is therefore null in this index, which is the honest position rather than an omission.
key published findings
- PubMed returns no records for ‘vesilute’: the search engine explicitly reports that the term retrieved no results and substitutes an unrelated term, so there is no indexed scientific literature on the compound at all.
- ClinicalTrials.gov contains no registered study of Vesilute or any sibling bioregulator in this batch.
- The originator-linked product listing declares the active as ‘peptide AKS-M (L-aspartic acid; L-glutamic acid)’ in oral capsules with microcrystalline cellulose, sugar, lactose, starch and Tween-80 excipients, manufactured by TD Peptid Bio with the St Petersburg Institute of Bioregulation and Gerontology.
- A research-reagent vendor assigns Vesilut the sequence H-Lys-Glu-Asp-OH with C15H26N4O8 and 390.39 g/mol — identical to Vesugen — but quotes CAS 76101-86-5, which conflicts with PubChem's CAS 204271-66-9 for Lys-Glu-Asp.
- Other vendor descriptions give the sequence as Glu-Asp, and at least one markets Vesilute as a ‘vascular bioregulator’, which is Vesugen's claimed indication rather than a urinary one.
- Clinical data on bladder peptide preparations traces to Vesusten, a bovine bladder peptide complex: a Russian urology review reports phase I in 32 volunteers and randomised placebo-controlled phase II and III studies in 108 and 150 overactive-bladder patients, with 54.05 percent marked improvement claimed in phase III — none of which is evidence about Vesilute.
limitations of the evidence
- There is no published study of Vesilute of any kind — not human, not animal, not in vitro — so there is no evidence base to grade beyond an absence.
- The compound's chemical identity is unresolved and vendor listings contradict each other on sequence and CAS number, meaning material bought under this name cannot be assumed to be the same molecule between suppliers.
- The bladder clinical data in circulation belongs to Vesusten, a different bovine-extract preparation, and presenting it as support for Vesilute is borrowed evidence.
- Sources here are necessarily shared with the other Khavinson bioregulators, and the family-level reviews cited make no compound-specific claim about Vesilute; they should not be read as support for it.
- The originating group's own 2013 review of clinical results for its bioregulators does not mention Vesilute, so even the developers have not claimed clinical results for it.
- The Russian product is a supplement-category capsule carrying disease claims about cystitis, prostatitis, incontinence and benign prostatic hyperplasia that no regulator has evaluated.
documented safety signals
- No safety signals are documented, and no safety study of any kind exists — absence of reported harm reflects absence of study and absence of monitored exposure, not demonstrated safety.
- The specific hazard here is identity rather than toxicity: material of unverified composition cannot be risk-assessed, and different suppliers appear to be selling chemically different substances under one name.
- The originator product is a capsule containing lactose and other excipients, which is relevant only in that it confirms the material is not a characterised single peptide.
- Research-grade material has no regulator-audited manufacturing standard, so impurity, endotoxin and peptide-content risk are entirely unquantified, and no pharmacovigilance system covers it anywhere.
identity
| full name | Vesilute / Vesilut (bladder ‘bioregulator’; sequence not established) |
| category | Other |
| modality | other |
laboratory handling
| storage | Laboratory handling only: in the absence of any established identity, treat as an uncharacterised lyophilised peptide preparation — keep frozen, desiccated and protected from light, thaw once, aliquot, and avoid repeated freeze-thaw. Because supplier-to-supplier composition cannot be assumed consistent, each batch should be independently identity-checked before any experimental use. |
| solubility | Laboratory solubility only: no characterised solubility data exist for this material because its chemical identity is not established in the published record. Any handling protocol must be determined empirically for the specific batch received. |
| co-studied with | Vesilute is sold as part of Cytogen stacks, but since its identity is unestablished and at least one supplier ships what appears to be Vesugen under the name, stacking it with Vesugen risks duplicating the same material while attributing effects to two different products. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedPubMed, US National Library of Medicine · 2026 · official
ClinicalTrials.gov, US National Library of Medicine · 2026 · official
Urologiia (Russian urology journal) · 2023 · review
Advances in Gerontology / Uspekhi Gerontologii · 2013 · review
Peptide-Products / Cytogens originator product catalogue · 2026 · tertiary
AminoCore Research (research-reagent vendor) · 2026 · tertiary
Sources marked tertiary or press release are the weakest citations on this page.
others in Other